Cited by 182Dementia and Cognitive Impairment ResearchCerebrovascular and genetic disordersNeurological Disease Mechanisms and Treatments

A New Visual Rating Scale to Assess Strategic White Matter Hyperintensities Within Cholinergic Pathways in Dementia

Open access
Bocti, Christian, Swartz, Richard H., Gao, Fu-Qiang, Sahlas, Demetrios J., Behl, Pearl, Black, Sandra E.·2005·Stroke

Abstract

Background and Purpose— One possible mechanism of cognitive decline in individuals with subcortical vascular disease is disruption of cholinergic fibers by ischemic lesions, such as strategically located white matter hyperintensities (WMH). The authors applied a new MRI visual rating scale to assess WMH within cholinergic pathways in patients with Alzheimer Disease (AD) and subcortical ischemic microvascular disease. Methods— Subjects included 60 AD patients with and without WMH, matched for age, as well as 15 control subjects. A visual rating scale was developed based on published immunohistochemical tracings of the cholinergic pathways in humans. On 4 selected axial images, the severity of WMH in the cholinergic pathways was rated on a 3-point scale for ten regions, identified with major anatomical landmarks. A published, consensus-derived, general WMH scale was also applied. All subjects underwent standardized neuropsychological testing. Results— The Cholinergic Pathways HyperIntensities Scale showed reliability and was validated with volumetry of strategic WMH. After accounting for age and education in a multiple linear regression model, The Cholinergic Pathways HyperIntensities Scale ratings were associated with impaired performance on the Mattis Dementia Rating Scale ( r =0.40; P =0.02) and accounted for 12% of the variance (corrected r 2 ). A similar model was not significant for general WMH scores. Conclusions— The new MRI rating scale for WMH in cholinergic pathways is reliable and shows stronger correlations with cognitive performance than a general WMH rating scale in AD with WMH. This new rating scale provides indirect evidence that localization of WMH within neurotransmitter systems may contribute to cognitive decline.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.str.0000183615.07936.b6

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Donepezil produced cognitive benefit in VaD, but global and functional efficacy was less consistent across individual studies.

    “Cognitive benefit was found, but global and functional efficacy was less consistent in the individual studies.396,400”

    From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [396]

    The Discussion (page unavailable) examines white matter hyperintensities and cognition, and says their effect on response to cholinesterase inhibitors remains to be determined. Searches for donepezil and for global and functional treatment outcomes found no passage assessing those outcomes in vascular dementia. (LLM, conf=0.75)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 38 · Cited by 182

Research works printed but not linked: 4

  1. de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, Breteler MM. Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. Ann Neurol. 2000;47:145-151.
  2. Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu TB, eds. Geriatric Psychiatry. New York: Grune & Stratton; 1976:108 -121.
  3. Lezak M. Neuropsychological Assessment. New York: Oxford Uni- versity Press; 1995.
  4. Quddus A, Lobaugh NJ, Ramirez J, Levine B, Feinstein A, Black SE. Robust protocol for the segmentation of subcortical hyperintensities on MRI scans. J Neurol Sci. 2003;226:148 -149 (Abstract).

Authors
Bocti, C., Swartz, R. H., Gao, F.-Q., Sahlas, D. J., Behl, P., & Black, S. E.
Affiliations
  • Sunnybrook Health Science Centre (CA)
  • From the Division of Neurology (C.B), Department of Medicine, Maisonneuve-Rosemont Hospital, University of Montreal, and the Department of Clinical Neurosciences (C.B.), Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada; and Linda C. Campbell Cognitive Research Unit (R.H.S., F.-Q.G., D.J.S., P.B., S.E.B.), Department of Medicine (Division of Neurology), and Heart and Stroke Foundation of Ontario Centre for Stroke Recovery, Sunnybrook and Women’s College Health...
Venue
Stroke
Published
2005-10
Volume
36
Issue
10
Pages
2126-2131
ISSN
  • 0039-2499 (ISSN-L)
  • 1524-4628
OpenAlex
W2170621670
Cited by
182
References
38
Citations by year
2026: 4 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 4 · 2020: 2 · 2019: 8 · 2018: 4 · 2017: 10 · 2016: 7 · 2015: 8 · 2014: 7 · 2013: 10 · 2012: 9
FWCI
3.81
Type
journal article
Language
en
Open access
Locations
  • Stroke (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alzheimer Society
  • Canadian Institutes of Health Research (MT13129)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Cerebrovascular and genetic disorders
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
white matter hyperintensities, cholinergic pathways, Alzheimer's disease, visual rating scale, cognitive decline, Mattis Dementia Rating Scale
MeSH terms
Age Factors, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Immunohistochemistry, Ischemia, Magnetic Resonance Imaging, Male, Mental Status Schedule, Microcirculation, Neurons, Neuropsychological Tests, Receptors, Cholinergic, Severity of Illness Index, Time Factors, Visual Perception, Dementia, Vascular, Models, Statistical, Case-Control Studies, Neurotransmitter Agents, Leukoaraiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review